Flavonoids, which reduce the growth of cancer, available for r & d on cancer cells.

Perth, Australia, August 16, 2011- / PRNewswire / – Heartlink Limited, based in Australia, is developing patented synthetic compounds based on the structure of isoflavones that have proved effective against cancer in laboratory studies and in animals at low doses. The compounds tested so far show low levels of toxicity to normal mammalian cells.

The exploration of in-vitro initial drug study revealed activity of compounds selected from a panel of nine lines of cancerous human cells using a trial of standard cell proliferation. Affirmative results showed drastic effects antiprofilerativos and cytotoxic to a range of tumour cell lines (with the highest activity against prostate cancer and cervical) after treatment with three of the company’s patented compounds

An in-vivo study designed to test the effectiveness of two compounds tested against tumors had a positive outcome. The compounds were tested for active anti-cancer in a range of doses in a model of mouse using human prostate cancer cells. The results showed a reduction in the relative controls substantial 42% after 14 days of treatment at levels of low-dose (10 mg/kg).

The isoflavones are known to have anticancer activity particularly in cancers based on hormones, such as the ovarian, breast and prostate. Heartlink has identified, evaluated and patented a family of compounds related to the isoflavones. Patents cover a wide range of therapeutic uses and detail the specific routes for the production and manufacturing along with the potential formulations for therapeutic use.

According to delegate Councillor of Heartlink, Tracey-Anne Dickens, said: “the activities of research to date have offered valuable Preclinical data for the development of this family of compounds isoflavones that could prove a useful source for the development of drugs against cancer.” “Collected information provides a foundation in which develop patented compounds and we are actively seeking partnerships for research and development or marketing”.

About Heartlink Limited

Founded in January 2000, the company has funded clinical research and product development and now has a medical device of second generation that can be used for research and development applications. Heartlink is also a drug discovery company and has been identified and patented composite isoflavones-derived anticancer compounds. Preclinical studies on the company’s patented compounds have shown an important activity that provides a basis for further evaluation of these new treatment against cancer.